The European Centre for Disease Prevention and Control (ECDC) warned on Wednesday that the European Union is off track to meet its 2030 antimicrobial resistance targets. Its new surveillance data showed bloodstream infections caused by carbapenem-resistant Klebsiella pneumoniae still rising sharply. The figures, released in Stockholm on European Antibiotic Awareness Day, show estimated incidence of these infections remains more than 50% above the 2019 baseline.
The targets were set in a 2023 Council Recommendation adopted by EU health ministers. They commit member states to cutting total human antibiotic consumption by 20% by 2030 and reducing carbapenem-resistant K. pneumoniae bloodstream infections by 5%. Other targets require a 15% fall in MRSA and a 10% fall in E. coli resistant to third-generation cephalosporins.
The agency said MRSA bloodstream infections continued their long decline and were broadly on course to meet the 2030 goal. Progress on antibiotic consumption was described by the ECDC as too slow. It said several member states were still prescribing well above the EU average, particularly in community settings. Carbapenems are last-line antibiotics, and the ECDC said resistance to them leaves clinicians with few or no effective treatment options.
The data were published at the start of World AMR Awareness Week, which runs until 24 November and is coordinated by the World Health Organization. The ECDC urged governments to strengthen infection prevention in hospitals, expand screening of patients transferred between facilities and improve prudent prescribing. It said hospital-acquired spread, rather than travel alone, was driving much of the rise in resistant Klebsiella.
In the United Kingdom, the UK Health Security Agency used the same awareness week to highlight its own surveillance of resistant infections in England. Public health bodies across Europe said the coming winter respiratory season, when antibiotics are often wrongly prescribed for viral illnesses, posed a particular risk of further overuse.